John Cox

Sanofi Pasteur HQ

Pharma

Sanofi snaps up Biogen's spun-out Bioverativ in $11.6B deal

Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.

Tracy Staton Jan 22, 2018 6:45am

Blood pricked finger

Bioverativ aims to keep parent Biogen's 'patient-centric' image

Feb 1, 2017 9:58am

shire

Bioverativ remind you of Baxalta? Rethink that, execs say

Jan 11, 2017 8:30pm